Oparta (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate)

Beclometasone dipropionate, the active ingredient in Oparta, is a corticosteroid combined with a long‑acting beta‑2 agonist presented as a metered‑dose inhaler for inhalation use. It is indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease in adults and adolescents. GNH USA supplies Oparta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oparta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oparta is a combination inhaled therapy that targets airway inflammation and bronchoconstriction in chronic respiratory disease.

- Asthma: improves lung function and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): helps maintain airflow and decreases symptom variability. - Exercise‑induced bronchoconstriction: provides pre‑exercise bronchodilation and inflammation control.

Adverse reactions may occur with inhaled corticosteroid/long‑acting β2‑agonist combinations and should be monitored.

Common Side Effects: - Oral thrush (candidiasis): fungal growth in the mouth. - Hoarseness: voice changes after inhalation. - Cough: irritation of the throat. - Headache: mild to moderate intensity. - Nasal congestion: blockage of nasal passages. - Upper respiratory tract infection: mild viral symptoms.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Pneumonia: lung infection, especially in COPD patients. - Adrenal suppression: reduced cortisol production with prolonged high‑dose use. - Glaucoma or cataracts: increased intra‑ocular pressure or lens opacity. - Severe allergic reaction: hives, swelling, or anaphylaxis. - Osteoporosis: decreased bone mineral density with long‑term use.

When prescribing Oparta, clinicians should consider several safety aspects.

- Assess asthma or COPD control: ensure the patient remains stable on current therapy. - Monitor for oral candidiasis: advise rinsing mouth after each inhalation. - Evaluate cardiovascular risk: beta‑agonists can affect heart rate and blood pressure. - Review concomitant medications: avoid excessive systemic corticosteroid exposure. - Use the lowest effective dose: limit exposure to inhaled steroids. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Oparta may interact with other medicines that influence the cardiovascular or immune systems.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator response and provoke bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase systemic exposure to beclometasone.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypokalemia risk when combined with long‑acting β2‑agonists.\n- Theophylline: may increase the risk of tachycardia and tremor. - Non‑selective NSAIDs: can exacerbate asthma symptoms in sensitive individuals. - Anticholinergic bronchodilators: additive bronchodilation may require dose adjustment.